Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256. No abstract available.

PMID:
31603413
2.

Response of Primary Renal Cell Carcinoma to Systemic Therapy.

Bossé D, Lin X, Simantov R, Lalani AA, Derweesh I, Chang SL, Choueiri TK, McKay RR.

Eur Urol. 2019 Oct 5. pii: S0302-2838(19)30685-2. doi: 10.1016/j.eururo.2019.08.035. [Epub ahead of print]

PMID:
31594707
3.

Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.

Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, Choueiri TK.

Eur Urol Oncol. 2019 Sep 24. pii: S2588-9311(19)30142-7. doi: 10.1016/j.euo.2019.09.001. [Epub ahead of print]

PMID:
31562048
4.

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.

Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, Choueiri TK, Giannakis M.

Nat Commun. 2019 Sep 25;10(1):4346. doi: 10.1038/s41467-019-12361-9.

5.

The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.

Lysyy T, Lalani AS, Olek EA, Diala I, Geibel JP.

Pharmacol Res Perspect. 2019 Sep 13;7(5):e00521. doi: 10.1002/prp2.521. eCollection 2019 Oct.

6.

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2019 Aug 20;10(49):5120-5122. doi: 10.18632/oncotarget.27162. eCollection 2019 Aug 20.

7.

Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.

Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP.

Eur Urol Oncol. 2019 Mar 9. pii: S2588-9311(19)30028-8. doi: 10.1016/j.euo.2019.02.004. [Epub ahead of print]

PMID:
31412004
8.

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis.

Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, Diala I, Lalani A, Loi S, David S, Anderson RL, Smith Y, Merino D, Denoyer D, Pouliot N.

Breast Cancer Res. 2019 Aug 13;21(1):94. doi: 10.1186/s13058-019-1177-1.

9.

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.

Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF.

Oncogene. 2019 Jul;38(30):5890-5904. doi: 10.1038/s41388-019-0849-8. Epub 2019 Jun 28.

PMID:
31253872
10.

Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA.

Can Urol Assoc J. 2019 Jun;13(6):166-174. doi: 10.5489/cuaj.5786. No abstract available.

11.

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh E, Ray S, Ngo LT, Kivitz S, Pasetto A, Yossef R, Lowery FJ, Goff SL, Lo W, Cafri G, Deniger DC, Malekzadeh P, Ahmadzadeh M, Wunderlich JR, Somerville RPT, Rosenberg SA.

Cancer Discov. 2019 Aug;9(8):1022-1035. doi: 10.1158/2159-8290.CD-18-1494. Epub 2019 Jun 4.

PMID:
31164343
12.

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J.

Cancers (Basel). 2019 May 28;11(6). pii: E737. doi: 10.3390/cancers11060737. Review.

13.

Age-Related Decline in Patient-Reported Outcomes 2 and 5 Years Following Total Hip Arthroplasty.

Lalani A, Lee YY, Pitta M, Westrich GH, Lyman S.

J Arthroplasty. 2019 Sep;34(9):1999-2005. doi: 10.1016/j.arth.2019.02.023. Epub 2019 Feb 20.

PMID:
30979671
14.

Influence of Lifestyle Factors on Oral Health-Related Quality of Life in Pregnant Women in Indore City.

Kumar S, Badiyani BK, Lalani A, Kumar A, Roy S.

Malays J Med Sci. 2018 Mar;25(2):126-132. doi: 10.21315/mjms2018.25.2.13. Epub 2018 Apr 27.

15.

Prevalence of Tobacco and associated risk factors among university law students in Indore City.

Gupta S, Mishra P, Nagarajappa S, Kumar S, Lalani A.

Indian J Dent Res. 2019 Jan-Feb;30(1):10-14. doi: 10.4103/ijdr.IJDR_228_17.

16.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A.

Breast Cancer Res. 2019 Mar 11;21(1):39. doi: 10.1186/s13058-019-1115-2.

17.

State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.

Bakouny Z, Flippot R, Braun DA, Lalani AA, Choueiri TK.

Eur Urol Focus. 2019 Feb 28. pii: S2405-4569(19)30049-5. doi: 10.1016/j.euf.2019.02.014. [Epub ahead of print] Review.

PMID:
30827939
18.

Early Active Motion Versus Sling Immobilization After Arthroscopic Rotator Cuff Repair: A Randomized Controlled Trial.

Sheps DM, Silveira A, Beaupre L, Styles-Tripp F, Balyk R, Lalani A, Glasgow R, Bergman J, Bouliane M; Shoulder and Upper Extremity Research Group of Edmonton (SURGE).

Arthroscopy. 2019 Mar;35(3):749-760.e2. doi: 10.1016/j.arthro.2018.10.139.

PMID:
30827428
19.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

PMID:
30755741
20.

Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2019 Feb;9(2):303. doi: 10.1158/2159-8290.CD-18-1515. No abstract available.

PMID:
30737217
21.

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.

Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, Hancock JF, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(5):700-710. doi: 10.1080/15384047.2018.1551747. Epub 2018 Dec 20.

PMID:
30571927
22.

Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.

Jongen L, Floris G, Boeckx B, Smeets D, Lambrechts D, Vander Borght S, Laenen A, Mann G, Cutler RE Jr, Lalani AS, Neven P, Wildiers H.

Breast Cancer Res Treat. 2019 Feb;174(1):55-63. doi: 10.1007/s10549-018-5049-7. Epub 2018 Nov 19.

PMID:
30456437
23.

Systemic treatments for metastatic urothelial carcinoma.

Lalani AA, Sonpavde GP.

Expert Opin Pharmacother. 2019 Feb;20(2):201-208. doi: 10.1080/14656566.2018.1544242. Epub 2018 Nov 9. Review.

PMID:
30412003
24.

Age-Related Functional Decline Following Total Knee Arthroplasty: Risk Adjustment is Mandatory.

Pitta M, Khoshbin A, Lalani A, Lee LY, Woo P, Westrich GH, Lyman S.

J Arthroplasty. 2019 Feb;34(2):228-234. doi: 10.1016/j.arth.2018.09.046. Epub 2018 Sep 22.

PMID:
30385091
25.

Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.

Lalani AA, McGregor BA, Albiges L, Choueiri TK, Motzer R, Powles T, Wood C, Bex A.

Eur Urol. 2019 Jan;75(1):100-110. doi: 10.1016/j.eururo.2018.10.010. Epub 2018 Oct 13. Review.

PMID:
30327274
26.

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.

Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE Jr, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL.

Clin Cancer Res. 2019 Jan 1;25(1):277-289. doi: 10.1158/1078-0432.CCR-18-1544. Epub 2018 Oct 12.

PMID:
30314968
27.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

28.

Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.

Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL.

Clin Cancer Res. 2019 Jan 15;25(2):771-783. doi: 10.1158/1078-0432.CCR-18-1131. Epub 2018 Oct 1.

30.

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE.

Br J Cancer. 2018 Sep;119(6):707-712. doi: 10.1038/s41416-018-0261-0. Epub 2018 Sep 17.

31.

Neratinib augments the lethality of [regorafenib + sildenafil].

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Hancock JF, Poklepovic A, Dent P.

J Cell Physiol. 2019 Apr;234(4):4874-4887. doi: 10.1002/jcp.27276. Epub 2018 Sep 10.

PMID:
30203445
32.

Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.

Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2019;20(2):157-168. doi: 10.1080/15384047.2018.1507665. Epub 2018 Sep 5.

34.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA.

Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1.

35.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May;118(11):1434-1441. doi: 10.1038/s41416-018-0087-9. Epub 2018 May 16.

36.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

37.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

38.

TRAF molecules in inflammation and inflammatory diseases.

Lalani AI, Zhu S, Gokhale S, Jin J, Xie P.

Curr Pharmacol Rep. 2018 Feb;4(1):64-90. doi: 10.1007/s40495-017-0117-y. Epub 2017 Dec 20.

39.

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Booth L, Roberts JL, Rais R, Kirkwood J, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Oncotarget. 2017 Dec 26;9(5):6062-6074. doi: 10.18632/oncotarget.23681. eCollection 2018 Jan 19.

40.

Assessment of orthodontic treatment need among tribal children of Indore division, Central India.

Muralidharan S, Chauhan A, Gowda S, Ambekar R, Rathore BS, Chabra S, Lalani A, Harani H.

Clujul Med. 2018;91(1):104-111. doi: 10.15386/cjmed-795. Epub 2018 Jan 15.

41.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

42.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12.

43.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.

Booth L, Roberts JL, Samuel P, Avogadri-Connors F, Cutler RE, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Jun 3;19(6):525-533. doi: 10.1080/15384047.2018.1436024. Epub 2018 Mar 6.

44.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

45.

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.

Booth L, Roberts JL, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Poklepovic A, Dent P.

Cancer Biol Ther. 2018 Mar 4;19(3):239-247. doi: 10.1080/15384047.2018.1423927. Epub 2018 Jan 22.

PMID:
29333953
46.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

47.

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dent P.

Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.

48.

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK.

Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. No abstract available.

PMID:
29217289
49.

Immunotherapy in the Elderly.

Lalani AA, Bossé D, McGregor BA, Choueiri TK.

Eur Urol Focus. 2017 Oct;3(4-5):403-412. doi: 10.1016/j.euf.2017.11.008. Epub 2017 Nov 26. Review.

PMID:
29183736
50.

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, Lalani AS, Dent P.

Oncotarget. 2017 Oct 9;8(52):90262-90277. doi: 10.18632/oncotarget.21660. eCollection 2017 Oct 27. Erratum in: Oncotarget. 2019 Aug 20;10(49):5120-5122.

Supplemental Content

Loading ...
Support Center